GLOBAL COMPANION DIAGNOSTICS MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

GLOBAL COMPANION DIAGNOSTICS MARKET 2022-2028

Market by Mechanism, Indicator, Consumer, Commodity, and Regional Outlook | Forecast 2022-2028

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

A companion diagnostic, as defined by the Food and Drug Administration (FDA), is a medical device, more frequently an in-vitro diagnostic tool, that presents crucial data for the safe and efficient use of a matching drug or therapy. A healthcare provider can use companion diagnostic tests to assess whether a certain treatment product will give patients more advantages than hazards. Moreover, it is personalized medicine that encompasses drug testing, therapies, clinical trials, and research. It increases the effectiveness of pharmaceuticals as therapeutic agents and lowers the overall cost of healthcare during treatment.

According to Triton Market Research Analysis, the Global Companion Diagnostics Market was valued at $5314.48 million in 2021 and is expected to reach $12740.68 million by 2028, growing at a CAGR of 12.84% during the forecast period 2022-2028.

 


 

Click here to check out our blog on the Global Companion Diagnostics Market

MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND TRENDS

Over the forecast period, the market expansion is likely to be fueled by increasing incidences of medication reactions, surging cancer cases and fatalities, and the rising prevalence of precision medicines. Precision medicine, a patient-centered treatment strategy based on biomarker research, holds promise in bringing a paradigm shift in the healthcare sector, making it easier to eliminate the uncertainty associated with medication trial and error. This ultimately eradicates needless healthcare spending. As a result, the medical profession has been accepting precision medicine. The development of cutting-edge technologies, including next-generation sequencing (NGS), liquid biopsy, and companion diagnostics (CDx), has also been made possible by advances in genomics, proteomics, molecular biology, data analytics, and technical engineering.

The market, however, must overcome significant obstacles like the weak reimbursement framework and common cases of leakage in oncology companion diagnostics. To guarantee patient access to cutting-edge medical facilities and support ongoing innovation in medical technologies, reimbursement coverage and payment policies in public and private sectors are crucial. However, as healthcare prices rise, legislators and insurance companies become less supportive, reducing patient access to CDx testing and hindering companion diagnostics R&D.

Nevertheless, the ongoing research and investments in next generation gene sequencing are expected to create varied opportunities for the market. NGS-based diagnostics, like the FoundationOne CDx from F Hoffmann-La Roche, aid in determining the most suitable course of treatment for each patient, thereby minimizing the use of trial-and-error methods in medicine. Several businesses are investing in creating tailored therapies, heavily impacting the expansion of the precision medicine sector. Besides, the Centers for Medicare & Medicaid Services (CMS) announced that beneficiaries with advanced cancer would receive coverage for companion diagnostics based on next-generation sequencing, removing the control of local contractors over coverage and enabling more uniform access to tests.



Report scope can be customized per your requirements. Request For Customization 

KEY GEOGRAPHIES COVERED:

•         North America: United States and Canada

•         Europe: United Kingdom, France, Germany, Spain, Italy, Poland, and Rest of Europe

•         Asia-Pacific: China, Japan, India, South Korea, ASEAN Countries, Australia & New Zealand, and Rest of Asia-Pacific

•         Latin America: Brazil, Mexico, and Rest of Latin America

•         Middle East and Africa: Saudi Arabia, Turkey, United Arab Emirates, South Africa, and Rest of Middle East & Africa


SEGMENTATION ANALYSIS - COMPANION DIAGNOSTICS MARKET:

•         Market by Mechanism:

           o        In-Situ Hybridization

           o        Polymerase Chain Reaction

PCR is one of the most popular tests in the companion diagnostics market, which had a share of 38% in 2021. Due to its effective use of biomarkers in treating leukemia, prostate, and ovarian cancer, the PCR-based companion diagnostics market is anticipated to maintain its dominant position. Additionally, PCR continues to be in demand since it is used as a validation approach for NGS-based companion diagnostics.

           o        Immunohistochemistry

           o        Next Generation Sequencing

           o        Other Mechanisms

•         Market by Consumer:

           o        Pharmaceutical and Biopharmaceutical Companies

           o        Reference Laboratories

           o        Other Consumers

•         Market by Commodity:

           o        Assay Kits & Reagents

           o        Software & Services

•         Market by Indicator:

           o        Oncology

The oncology industry extensively uses companion diagnostic tools to produce extremely precise treatments or medications for specific cancer situations. An increase in cancer cases worldwide is anticipated to hasten the use of companion diagnostics devices. In addition, according to sources, Thermo Fisher Scientific and Cancer Genetics Inc worked together in the latter's next-generation sequencing (NGS) companion diagnostics center of excellence program to further research on cancer diagnostics.

            o       Neurology

            o       Infectious Disease

            o       Other Indicators

 

COMPETITIVE LANDSCAPE:

The companion diagnostics market by company profile helps dive into data about the key players in this industry. The strategic initiatives for each of the companies considered have been covered in detail.

Collaboration (November 2021): Arup Laboratories and PacBio

In November 2021, PacBio, a preeminent supplier of high-quality sequencing technologies, and ARUP Laboratories declared their partnership to determine whether it is possible to raise the solution rate for instances of rare diseases.

Product Launch (February 2020) BioMerieux

In-vitro diagnostics' leading company, BioMerieux, introduced MYACUTECASETM in February 2020. The first mobile application created by BioMerieux interprets VIDAS emergency and critical care biomarker tests.

 

KEY BENEFITS OF THE REPORT:

      Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.

 

      Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.

 

      The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.

 

      The scope of the market report comprises the current scenario of the global companion diagnostics market, along with the detailed overview of the industry outlook, market dynamics, segmentation analysis, regional outlook, and competitive landscape for the period 2022-2028.

 

FAQs:

Q 1) Does this report include the impact of COVID-19 on the Companion Diagnostics market?

The market study has analyzed the impact of COVID-19 on the companion diagnostics market qualitatively as well as quantitatively.

Q 2) Which type of mechanism covered the major market share in 2021?

The majority of market share was held by polymerase chain reaction, accounting for around 38% in 2021. 

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. GLOBAL COMPANION DIAGNOSTICS MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET

2.2. KEY INSIGHTS

2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT

2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS

2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. KEY BUYING IMPACT ANALYSIS

2.4.1. COST

2.4.2. AVAILABILITY

2.4.3. SENSITIVITY & SPECIFICITY

2.4.4. EFFICACY

2.5. MARKET ATTRACTIVENESS INDEX

2.6. VENDOR SCORECARD

2.7. INDUSTRY COMPONENTS

2.8. REGULATORY FRAMEWORK

2.9. KEY MARKET STRATEGIES

2.9.1. ACQUISITIONS

2.9.2. PRODUCT LAUNCHES

2.9.3. CONTRACTS & AGREEMENTS

2.10. MARKET DRIVERS

2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS

2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES

2.10.3. RISING PREVALENCE OF PRECISION MEDICINES

2.11. MARKET CHALLENGES

2.11.1. WEAK REIMBURSEMENT FRAMEWORK

2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS

2.12. MARKET OPPORTUNITY

2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING

3. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK - BY MECHANISM

3.1. IN-SITU HYBRIDIZATION

3.2. POLYMERASE CHAIN REACTION

3.3. IMMUNOHISTOCHEMISTRY

3.4. NEXT GENERATION SEQUENCING

3.5. OTHER MECHANISMS

4. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK - BY INDICATOR

4.1. ONCOLOGY

4.2. NEUROLOGY

4.3. INFECTIOUS DISEASES

4.4. OTHER INDICATORS

5. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK - BY CONSUMER

5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES

5.2. REFERENCE LABORATORIES

5.3. OTHER CONSUMERS

6. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK - BY COMMODITY

6.1. ASSAY KITS AND REAGENTS

6.2. SOFTWARE AND SERVICES

7. GLOBAL COMPANION DIAGNOSTICS MARKET - REGIONAL OUTLOOK

7.1. NORTH AMERICA

7.1.1. MARKET OUTLOOK BY MECHANISM

7.1.2. MARKET OUTLOOK BY INDICATOR

7.1.3. MARKET OUTLOOK BY CONSUMER

7.1.4. MARKET OUTLOOK BY COMMODITY

7.1.5. COUNTRY ANALYSIS

7.1.5.1. UNITED STATES

7.1.5.2. CANADA

7.2. EUROPE

7.2.1. MARKET OUTLOOK BY MECHANISM

7.2.2. MARKET OUTLOOK BY INDICATOR

7.2.3. MARKET OUTLOOK BY CONSUMER

7.2.4. MARKET OUTLOOK BY COMMODITY

7.2.5. COUNTRY ANALYSIS

7.2.5.1. UNITED KINGDOM

7.2.5.2. GERMANY

7.2.5.3. FRANCE

7.2.5.4. SPAIN

7.2.5.5. ITALY

7.2.5.6. POLAND

7.2.5.7. REST OF EUROPE

7.3. ASIA-PACIFIC

7.3.1. MARKET OUTLOOK BY MECHANISM

7.3.2. MARKET OUTLOOK BY INDICATOR

7.3.3. MARKET OUTLOOK BY CONSUMER

7.3.4. MARKET OUTLOOK BY COMMODITY

7.3.5. COUNTRY ANALYSIS

7.3.5.1. CHINA

7.3.5.2. JAPAN

7.3.5.3. INDIA

7.3.5.4. SOUTH KOREA

7.3.5.5. ASEAN COUNTRIES

7.3.5.6. AUSTRALIA & NEW ZEALAND

7.3.5.7. REST OF ASIA-PACIFIC

7.4. LATIN AMERICA

7.4.1. MARKET OUTLOOK BY MECHANISM

7.4.2. MARKET OUTLOOK BY INDICATOR

7.4.3. MARKET OUTLOOK BY CONSUMER

7.4.4. MARKET OUTLOOK BY COMMODITY

7.4.5. COUNTRY ANALYSIS

7.4.5.1. BRAZIL

7.4.5.2. MEXICO

7.4.5.3. REST OF LATIN AMERICA

7.5. MIDDLE EAST AND AFRICA

7.5.1. MARKET OUTLOOK BY MECHANISM

7.5.2. MARKET OUTLOOK BY INDICATOR

7.5.3. MARKET OUTLOOK BY CONSUMER

7.5.4. MARKET OUTLOOK BY COMMODITY

7.5.5. COUNTRY ANALYSIS

7.5.5.1. UNITED ARAB EMIRATES

7.5.5.2. SAUDI ARABIA

7.5.5.3. TURKEY

7.5.5.4. SOUTH AFRICA

7.5.5.5. REST OF MIDDLE EAST & AFRICA

8. COMPETITIVE LANDSCAPE

8.1. ABBOTT LABORATORIES

8.2. ALMAC GROUP

8.3. ARUP LABORATORIES

8.4. BIOCARTIS

8.5. BIOMERIEUX

8.6. DANAHER CORPORATION

8.7. GE HEALTHCARE

8.8. GENOMIC HEALTH

8.9. ILLUMINA INC

8.10. MYRIAD GENETICS

8.11. QIAGEN

8.12. ROCHE DIAGNOSTICS

8.13. SYSMEX CORPORATION

8.14. THERMO FISHER SCIENTIFIC

8.15. AGILENT

9. RESEARCH METHODOLOGY & SCOPE

9.1. RESEARCH SCOPE & DELIVERABLES

9.2. SOURCES OF DATA

9.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: LIST OF ACQUISITIONS

TABLE 4: LIST OF PRODUCT LAUNCHES

TABLE 5: LIST OF CONTRACTS & AGREEMENTS

TABLE 6: NUMBER OF CANCER PATIENTS IN 2020

TABLE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 10: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 12: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 13: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 14: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 15: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 16: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 17: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 18: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 19: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 20: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 21: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 22: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 23: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 24: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 25: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 26: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 27: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 28: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 29: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 30: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 31: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 32: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)

TABLE 33: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)

TABLE 34: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)

TABLE 35: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)

TABLE 36: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: INDUSTRY COMPONENTS

FIGURE 3: FDA FRAMEWORK

FIGURE 4: CDX LEAKAGE POINTS

FIGURE 5: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)

FIGURE 6: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)

FIGURE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)

FIGURE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)

FIGURE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)

FIGURE 10: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)

FIGURE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)

FIGURE 12: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)

FIGURE 13: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)

FIGURE 14: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 15: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)

FIGURE 16: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)

FIGURE 17: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)

FIGURE 18: GLOBAL COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)

FIGURE 19: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)

FIGURE 20: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)

FIGURE 21: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)

FIGURE 22: GLOBAL COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)

FIGURE 23: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)

FIGURE 24: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021

FIGURE 25: UNITED STATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 26: CANADA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 27: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021

FIGURE 28: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 29: GERMANY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 30: FRANCE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 31: SPAIN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: ITALY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: POLAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: REST OF EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021

FIGURE 36: CHINA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 37: JAPAN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 38: INDIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 39: SOUTH KOREA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 40: ASEAN COUNTRIES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 41: AUSTRALIA & NEW ZEALAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 42: REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 43: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021

FIGURE 44: BRAZIL COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 45: MEXICO COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 46: REST OF LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 47: MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET COUNTRY OUTLOOK, 2021

FIGURE 48: UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 49: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 50: TURKEY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 51: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

FIGURE 52: REST OF MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying